Market Overview

Life Sciences Companies Move to Veeva Vault CTMS for Greater Visibility and Speed in Clinical Trials


Vault CTMS gives industry a new approach to streamline clinical trial

Over the past year, growing numbers of customers are adopting
Veeva Vault CTMS
to empower clinical teams with one complete source
of trial information for faster study execution. Vault CTMS is a
next-generation cloud application from Veeva
(NYSE:VEEV) that unifies end-to-end information and
processes for greater visibility throughout the trial lifecycle. In 15
months since the product's availability, 28 sponsors and CROs have
selected Vault CTMS and 18 customers are already using the product to
streamline clinical operations and improve trial performance.

"CTMS solutions have held the industry back for decades, and the
industry is recognizing the tremendous opportunity to improve efficiency
throughout its operations," said Henry Galio, senior director, Vault
CTMS. "Veeva Vault CTMS is finally giving customers a new, innovative
approach to CTMS for more efficient and effective trials."

A recent survey shows that challenges with current CTMS applications are
limiting trial operations for the majority of life sciences companies.1
Greater visibility is a top driver for clinical operations professionals
to improve the use of CTMS. 2

"Veeva Vault CTMS gives us a full view into trial tasks and processes to
make faster, more informed decisions throughout the course of a study,"
said Hunter Walker, CTO, Atlantic Research Group (ARG), a CRO that
specializes in managing rare disease clinical trials for multiple
sponsors. "Study managers and clinical research associates have an
intuitive, easy-to-use application to manage trial data, documents, and

Consistent with the industry's focus to improve operational performance,
more customers are using Vault CTMS to unify their clinical information
and processes and gain a global view into study execution. Clinical
teams can also leverage the same content and data across clinical
operations to streamline trial processes.

"With significant clinical trial timeline pressures, we needed a CTMS
solution we could implement quickly to simplify trial management across
our studies," said Jeff Reyes, R&D IT at Immunomedics. "Veeva Vault CTMS
gives us a modern application that works seamlessly with other Veeva
clinical applications to drive greater efficiency throughout our
clinical operations."

Vault CTMS is part of Veeva
Vault Clinical Suite
, the industry's first suite of applications
with CTMS, EDC, eTMF, and study start-up on a single cloud platform.
Vault Clinical Suite helps companies eliminate system silos and unify
clinical data management and clinical operations. Vault Clinical Suite
is part of Veeva
Development Cloud
, a unified suite of applications for clinical,
regulatory, and quality to help organizations drive end-to-end business
processes across R&D and manufacturing.

Veeva also announced today the availability of Veeva
Vault Submissions Publishing
, a new cloud application in the Veeva
Vault RIM Suite
to unify publishing and submission document
authoring. Read the Vault
Submissions Publishing news
to learn more.

Also, join 1,300 life sciences professionals and experts at the upcoming Veeva
R&D Summit
 in Philadelphia, September 16-18. Learn more,
register, and view the full agenda at

Additional Information

For more on Veeva Vault CTMS, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry and other regulated manufacturers. Committed to
innovation, product excellence, and customer success, Veeva has more
than 650 customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices throughout North America, Europe, Asia,
and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva's products and services, the results
from use of Veeva's products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva's historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva's expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva's financial results are included under the captions,
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," in the company's filing on Form
10-Q for the period ended April 30, 2018. This is available on the
company's website at
under the Investors section and on the SEC's website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

1 Veeva
2018 Unified Clinical Operations Survey

2 Veeva
2018 Unified Clinical Operations Survey

View Comments and Join the Discussion!